These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21241213)

  • 1. Abagovomab for ovarian cancer.
    Pfisterer J; Harter P; Simonelli C; Peters M; Berek J; Sabbatini P; du Bois A
    Expert Opin Biol Ther; 2011 Mar; 11(3):395-403. PubMed ID: 21241213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A robust immune system conditions the response to abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination in ovarian cancer patients.
    Battaglia A; Fossati M; Buzzonetti A; Scambia G; Fattorossi A
    Immunol Lett; 2017 Nov; 191():35-39. PubMed ID: 28919454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-idiotypic antibody abagovomab in advanced ovarian cancer.
    Bauerschlag DO; Schem C; Baumann K; Harter P; Hilpert F; Wagner U; du Bois A; Pfisterer J
    Future Oncol; 2008 Dec; 4(6):769-73. PubMed ID: 19086842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.
    Berek J; Taylor P; McGuire W; Smith LM; Schultes B; Nicodemus CF
    J Clin Oncol; 2009 Jan; 27(3):418-25. PubMed ID: 19075271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Sabbatini P; Dupont J; Aghajanian C; Derosa F; Poynor E; Anderson S; Hensley M; Livingston P; Iasonos A; Spriggs D; McGuire W; Reinartz S; Schneider S; Grande C; Lele S; Rodabaugh K; Kepner J; Ferrone S; Odunsi K
    Clin Cancer Res; 2006 Sep; 12(18):5503-10. PubMed ID: 17000686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial.
    Buzzonetti A; Fossati M; Catzola V; Scambia G; Fattorossi A; Battaglia A
    Cancer Immunol Immunother; 2014 Oct; 63(10):1037-45. PubMed ID: 24952307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.
    Grisham RN; Berek J; Pfisterer J; Sabbatini P
    Immunotherapy; 2011 Feb; 3(2):153-62. PubMed ID: 21322756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
    Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM; Method M
    J Immunother; 2009 Jan; 32(1):54-65. PubMed ID: 19307994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR.
    Pfisterer J; du Bois A; Sehouli J; Loibl S; Reinartz S; Reuss A; Canzler U; Belau A; Jackisch C; Kimmig R; Wollschlaeger K; Heilmann V; Hilpert F
    Ann Oncol; 2006 Oct; 17(10):1568-77. PubMed ID: 17005631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic therapy for ovarian cancer: current status and new treatments.
    Ozols RF
    Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic and immunologic therapies for ovarian cancer.
    Berek JS; Schultes BC; Nicodemus CF
    J Clin Oncol; 2003 May; 21(10 Suppl):168s-174s. PubMed ID: 12743131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.
    Keir CH; Vahdat LT
    Expert Opin Biol Ther; 2012 Feb; 12(2):259-63. PubMed ID: 22229970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current concepts of treatment strategies in advanced or recurrent ovarian cancer.
    Salzberg M; Thurlimann B; Bonnefois H; Fink D; Rochlitz C; von Moos R; Senn H
    Oncology; 2005; 68(4-6):293-8. PubMed ID: 16020955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer.
    Berek JS; Taylor PT; Gordon A; Cunningham MJ; Finkler N; Orr J; Rivkin S; Schultes BC; Whiteside TL; Nicodemus CF
    J Clin Oncol; 2004 Sep; 22(17):3507-16. PubMed ID: 15337799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for maintenance or consolidation therapy in ovarian cancer.
    Markman M
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):176-8. PubMed ID: 16224399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel poliglumex for ovarian cancer.
    Galic VL; Wright JD; Lewin SN; Herzog TJ
    Expert Opin Investig Drugs; 2011 Jun; 20(6):813-21. PubMed ID: 21470062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.